MA50356A - Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 - Google Patents

Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1

Info

Publication number
MA50356A
MA50356A MA050356A MA50356A MA50356A MA 50356 A MA50356 A MA 50356A MA 050356 A MA050356 A MA 050356A MA 50356 A MA50356 A MA 50356A MA 50356 A MA50356 A MA 50356A
Authority
MA
Morocco
Prior art keywords
bicyclic compounds
compounds intended
rip1 inhibitors
kinase
kinase rip1
Prior art date
Application number
MA050356A
Other languages
English (en)
Inventor
Huifen Chen
Blake Daniels
Gregory Hamilton
Snahel Patel
Craig Stivala
Guiling Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA50356A publication Critical patent/MA50356A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA050356A 2017-10-11 2018-10-10 Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 MA50356A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762570892P 2017-10-11 2017-10-11

Publications (1)

Publication Number Publication Date
MA50356A true MA50356A (fr) 2021-04-21

Family

ID=63840848

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050356A MA50356A (fr) 2017-10-11 2018-10-10 Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1

Country Status (19)

Country Link
US (1) US11673892B2 (fr)
EP (1) EP3694858B1 (fr)
JP (1) JP7362600B2 (fr)
KR (1) KR20200070297A (fr)
CN (1) CN111201229B (fr)
AU (1) AU2018348930A1 (fr)
BR (1) BR112020007067A2 (fr)
CA (1) CA3078653A1 (fr)
CL (1) CL2020000944A1 (fr)
CO (1) CO2020004977A2 (fr)
CR (1) CR20200151A (fr)
IL (1) IL273443A (fr)
MA (1) MA50356A (fr)
MX (1) MX2020003439A (fr)
PE (1) PE20211246A1 (fr)
PH (1) PH12020550253A1 (fr)
RU (1) RU2020114670A (fr)
SG (1) SG11202003283TA (fr)
WO (1) WO2019072942A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201831478A (zh) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
CA3185865A1 (fr) * 2017-07-14 2019-01-17 F. Hoffmann-La Roche Ag Composes cetoniques bicycliques et leurs procedes d'utilisation
CR20200168A (es) 2017-10-31 2020-07-12 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CN113302193A (zh) * 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
WO2023039795A1 (fr) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Inhibiteur de la kinase rip1 et son utilisation
WO2025261418A1 (fr) * 2024-06-19 2025-12-26 成都赜灵生物医药科技有限公司 Composés fusionnés à un aryle et leur utilisation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
AU8405691A (en) * 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (fr) 1997-06-13 2001-07-04 Sugen Inc Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
SK287857B6 (sk) 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
EP2147679B1 (fr) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions pour le transport de barrière hématoencéphalique
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7220833B2 (en) 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JP5161245B2 (ja) 2007-02-07 2013-03-13 ファイザー・インク ＰＫＣ阻害剤としての３−アミノ−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルボアルデヒド誘導体
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
EA021047B1 (ru) 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы
BR112014026176A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche dipiridilaminas substituídas e usos das mesmas
TWI498325B (zh) 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
MY182082A (en) 2013-05-01 2021-01-18 Hoffmann La Roche Biheteroaryl compounds and uses thereof
BR112015027381A8 (pt) 2013-05-01 2018-01-30 Hoffmann La Roche pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
AU2015304851A1 (en) 2014-08-21 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as RIP1 kinase inhibitors as medicaments
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
CA3094197C (fr) 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Lactames bicycliques et leurs methodes d'utilisation
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
JP2020536915A (ja) 2020-12-17
MX2020003439A (es) 2020-07-29
CL2020000944A1 (es) 2020-08-21
EP3694858A1 (fr) 2020-08-19
CN111201229B (zh) 2024-08-23
WO2019072942A1 (fr) 2019-04-18
JP7362600B2 (ja) 2023-10-17
KR20200070297A (ko) 2020-06-17
PH12020550253A1 (en) 2021-02-22
CR20200151A (es) 2020-05-23
CO2020004977A2 (es) 2020-05-05
SG11202003283TA (en) 2020-05-28
AU2018348930A1 (en) 2020-03-26
BR112020007067A2 (pt) 2020-10-06
US11673892B2 (en) 2023-06-13
CN111201229A (zh) 2020-05-26
CA3078653A1 (fr) 2019-04-18
RU2020114670A (ru) 2021-11-12
EP3694858B1 (fr) 2023-01-11
PE20211246A1 (es) 2021-07-13
US20200283446A1 (en) 2020-09-10
IL273443A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA50356A (fr) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
EP3442488A4 (fr) Compositions pour l'application topique de composés
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
EP3768661A4 (fr) Composés deutérés utilisés en tant qu'inhibiteurs de rock
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase